Becton, Dickinson and Company Q1 2026 Earnings Recap

Becton, Dickinson and Company reported stronger-than-expected Q1 results for fiscal 2026, driven by disciplined execution and robust growth across key areas, despite challenges in certain segments.

Key Takeaways

• Revenues reached $5.3 billion, with new segments growing by 2.5% supported by double-digit growth in biologic drug delivery and advanced tissue regeneration.
• Adjusted gross margin improved to 53.4%, and adjusted EPS was $2.91, both exceeding expectations.
• The company is set to close a significant Reverse Morris Trust transaction with Waters, unlocking $4 billion in cash, with plans to allocate $2 billion to share repurchases and $2 billion for debt reduction.
• Enhanced capital allocation strategy emphasizes share buybacks, consistent dividends, and focused M&A to drive return on invested capital.